Baird Downgrades Biogen (BIIB) to Underperform on Alzheimer's Hype, 'CTAP Looks Ripe for Downside'
Tweet Send to a Friend
(Updated - December 2, 2019 5:07 AM EST)(update comment)Baird analyst Brian Skorney downgraded Biogen (NASDAQ: BIIB) from Neutral to Underperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
